Inadequate enrollment

The purpose of this study is to determine the efficacy and safety of intravenous micafungin versus placebo as prophylactic therapy for invasive fungal infections in patients in the intensive care unit considered to be at high risk.

Inclusion Criteria

• Meets entry criteria for high risk

Exclusion Criteria

• Evidence of active invasive fungal infection
• Received more than one dose of systemic antifungal agent within 72 hours prior to first dose of study drug
• Known to be HIV positive who have CD4 count less than 500 cells/mm3
• Has life-expectancy of less than 72 hours or moribund